We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Les antiangiogéniques dans le cancer épithélial de l'ovaire : où en sommes-nous ?
- Authors
Cock, L.; Leblanc, J.; Kurtz, J.
- Abstract
The use of antiangiogenic drugs, besides chemotherapy, is a cornerstone for the treatment of epithelial ovarian cancer and is highly recommended in 2014. This review of the literature on this topic focuses on the most outstanding clinical trial results in which a number of drugs have been tested in France and worldwide, whereas only bevacizumab is, so far, approved. We review the major antiangiogenic drugs that have been investigated in epithelial ovarian cancer, and discuss, the forthcoming situation where multiple and relatively similar drugs will be challenging each other at all stages of the disease.
- Publication
Oncologie (Tech Science Press), 2014, Vol 16, Issue 6, p318
- ISSN
1292-3818
- Publication type
Article
- DOI
10.1007/s10269-014-2404-4